Dosage and Administration
IE=infective endocarditis; CAPD=continuous ambulatory peritoneal dialysis.
aPatients with CLCR <30 mL/min, including those on hemodialysis and with CAPD, were excluded from CUBICIN pivotal trials.
Preparation and administration for 30-minute intravenous infusion
Preparation and administration for 2-minute intravenous injection
CUBICIN concentration-time curve on day 1 in healthy adult volunteers2,3
aMedian for 30-minute IV infusion; mean for 2-minute IV injection.
INDICATIONS AND IMPORTANT SAFETY INFORMATION
LIMITATIONS OF USE
WARNINGS AND PRECAUTIONS
1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55. 2. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47(4):1318-1323; 3. Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64:151-158.